A retrospective study assessing the efficacy and safety of treatment with Calcitonin gene-related peptide monoclonal antibodies in patients aged 65 years and older who initiated therapy for migraine treatment at a headache center
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Erenumab (Primary) ; Fremanezumab (Primary) ; Galcanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 05 Aug 2022 New trial record
- 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society